Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nichi-Iko Resumes Production After Suspension

Firm Had Halted Operations At Namerikawa Facility Due To GMP Issues

Executive Summary

Nichi Iko says it has restarted production at its Namerikawa manufacturing plant after the Japanese firm was forced to suspend operations due to alleged GMP violations.

You may also be interested in...



Nichi-Iko Offers Heartfelt Apology As It Forecasts Huge Annual Loss

Nichi-Iko’s first-half financial results made for unhappy reading again as the company’s bottom line was battered by longstanding quality problems, leading the firm to announce huge projected losses for its current financial year ending in March 2022.

Nichi-Iko Slashes Profitability Guidance As Supply Issues Drag On

Nichi-Iko has been forced to cut dramatically its core operating profit guidance for its 2022 financial year, as it continues to deal with the fallout of its previously deficient Namerikawa manufacturing facility in the Toyama prefecture.

Nippon Chemiphar Successfully Reverses Decline

Japan’s Nippon Chemiphar gets a grip on a decline in pharmaceutical sales seen earlier this year, on the back of strong sales of generic drugs launched last year. The company also expects an upward impact from expanded sales of generic drugs achieved through sales channel diversification efforts for its current financial year ending 31 March 2022. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel